TORONTO, CANADA / ACCESSWIRE / OCTOBER 27, 2020 – Fibrocor Therapeutics Inc. (“Fibrocor” or “the Company”), a privately held developer of de novo therapeutics to treat Fibrosis, announced today the appointment of industry veteran William C. Fanslow Ph.D. as Senior Vice President of Drug Development.
William (Bill) Fanslow has over 20 years of experience in all areas of drug development, spanning both small molecules and biologics. Prior to joining Fibrocor, Bill spent 5 years at Sound Biologics in Bothell, Washington where he oversaw the company’s lead product candidate PSB205, from discovery to Investigational New Drug Filing (IND), into Phase 1 development. Previously, as Executive Director, Therapeutic Innovation Unit and the Oncology Therapeutic area, at Amgen Inc., Bill led 7 oncology programs from discovery through to IND, and he is the named inventor on over 50 patents.
“We are very pleased to welcome Bill Fanslow to the Fibrocor leadership team. We are excited to have an expert in the field of antibody development guide our lead program, FIB 918 for the treatment of multiple fibrotic disease indications”, stated Dr. Richard Gilbert, Chief Scientific Officer, Fibrocor. “We believe he will make an excellent addition to the team and are looking forward to working with him closely on all aspects of our drug discovery and development.”
“I am honored to join the Fibrocor team”, commented Bill Fanslow. “I am impressed by Fibrocor’s unique target identification platform that is based on interrogating gene expression in clinically relevant tissues. I joined Fibrocor to facilitate the movement of clinically validated targets into drug discovery and then early development. I look forward to developing medicines that treat the unmet need in fibrotic disease.”About Fibrocor Therapeutics Inc.
Fibrocor is a privately held, tissue specific, drug discovery company. It is pioneering the use of tissue specific therapeutics in the field of precision medicine and in particular, Fibrosis. The company has partnered with leading research institutes in Toronto, Canada, to aggregate and interrogate diseased fibrotic tissue samples in a number of organ systems to understand the genesis of the disease and its manifestations in fast progressing populations. For more information visit fibrocortherapeutics.com.
Media Relations
Julie A. Fotheringham
Partner, HAGEMAN Communications
Julie.fotheringham@hageman.ca
416.951.7988